Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33…
Iovance Announces Five-year Results of Amtagvi (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting
One-time Amtagvi Treatment Demonstrated Durable Responses and a Five-year Overall Survival Rate…
BitMart Research: MCP+AI Agent – New framework for AI applications
Mahe, Seychelles , May 09, 2025 (GLOBE NEWSWIRE) -- BitMart Research, the…
Louis Limited Introduces AI-Powered Financial Insights for Global Market
Louis Limited launches an AI-powered trading app globally that tracks traders' emotional…
Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
Antitumor activity observed with confirmed partial responses in 50% of patientsat highest…
Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis
ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor…
LEO Pharma Presents New Late-Breaking Delgocitinib Cream Data For the Third Consecutive Year at AAD 2025
The post hoc analysis investigated treatment responses in a patient subgroup with…
Agora Launches Conversational AI Engine for Seamless Voice AI Experiences
The new solution allows developers to use any AI model to create…
IMG Travel Outlook Survey Predicts Top Destinations and Travel Trends for 2025
INDIANAPOLIS, Jan. 30, 2025 /PRNewswire/ -- IMG (International Medical Group), an award-winning…
Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer
27% preliminary response rate observed in heavily pre-treated microsatellite stable colorectal cancer…